PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19100119-10	2008	The expressions of p-JAK2 and p-STAT3 as well as the expression of AGT mRNA and c-fos mRNA significantly activated by CT-1, which could be inhibited by SIM or Janus Kinase-selective inhibitor AG490.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	192-197	angiotensinogen	Rattus norvegicus	67-70	
30412649-11	2019	Moreover, the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the Janus-activated kinase (JAK)2 inhibitor AG490 suppressed Ang II-induced differentiation of BM-MSCs into keratinocytes.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	179-184	angiotensinogen	Rattus norvegicus	196-202	
9299374-10	1997	Selective inhibition of Jak2 kinase with AG-490 blocked formation of angiotensin II induced SIF complexes, suggesting that Jak2 kinase is required for cardiomyocyte SIF induction.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	41-47	angiotensinogen	Rattus norvegicus	69-83	
32620936-10	2021	Pretreatment of NRCMs with the Jak2 inhibitor AG490 (10 microM) blocked Ang II-induced reduction in GJA1-20k expression and Cx43 gap junction formation; knockdown of Jak2 in NRCMs significantly lessened Ang II-induced cardiomyocyte hypertrophy and normalized GJA1-20k expression and Cx43 gap junction formation.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	46-51	angiotensinogen	Rattus norvegicus	72-78	
32620936-10	2021	Pretreatment of NRCMs with the Jak2 inhibitor AG490 (10 microM) blocked Ang II-induced reduction in GJA1-20k expression and Cx43 gap junction formation; knockdown of Jak2 in NRCMs significantly lessened Ang II-induced cardiomyocyte hypertrophy and normalized GJA1-20k expression and Cx43 gap junction formation.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	46-51	angiotensinogen	Rattus norvegicus	203-209	
25088002-10	2014	Pretreatment of the cells with AG490, a JAK2 inhibitor, markedly inhibited Ang II-induced STAT3 phosphorylation on Tyr705 and fibronectin expression.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	31-36	angiotensinogen	Rattus norvegicus	75-81	
24058756-5	2012	The Ang II-mediated phosphorylation of both JAK2 and STAT3 was blocked by AG490, a selective JAK2 inhibitor.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	74-79	angiotensinogen	Rattus norvegicus	4-10	
15770649-5	2005	We also found that AGE (150 microg/ml) increased angiotensinogen protein at 2 days, which was attenuated by AG-490 (a JAK2 inhibitor).	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	108-114	angiotensinogen	Rattus norvegicus	49-64	
15770649-9	2005	AG-490 and CTGF antisense (but not sense) oligodeoxynucleotide (ODN) attenuated Ang II (10(-7)M) and AGE-induced mitogenesis and type I collagen production at 3 and 7 days, respectively.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	0-6	angiotensinogen	Rattus norvegicus	80-86	
10884366-9	2000	Additionally, a Jak2 inhibitor, AG490, blocked the Ang II-induced Stat3 phosphorylation.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	32-37	angiotensinogen	Rattus norvegicus	51-57	
9732408-9	1998	The nonflavone tyrosine kinase inhibitor tyrphostin B42 (30 microM) reduced Ang II-induced maximal contraction (to 11.2% control) but, unlike the other tyrosine kinase inhibitors, also reduced KCl-induced contraction (to 55.2% control), indicating a probable nonselectivity of tyrphostin B42.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	41-55	angiotensinogen	Rattus norvegicus	76-82	
9602424-13	1998	Selective inhibition of Jak2 kinase with AG-490 blocked formation of prolactin-inducing factor (PIF) complexes by Ang II, suggesting that Jak2 kinase was required for the tyrosine phosphorylation of Stat5 in cardiac myocytes.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	41-47	angiotensinogen	Rattus norvegicus	114-120